

Evan Y Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3118779/publications.pdf>

Version: 2024-02-01

115
papers

10,423
citations

136950

32
h-index

33894

99
g-index

116
all docs

116
docs citations

116
times ranked

13142
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of prior local therapy and outcomes with programmedâ€œdeath ligandâ€œ1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.	2.5	3
2	A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2022, 7, 100858.	1.2	3
3	Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. <i>Journal of Clinical Oncology</i> , 2022, 40, 1500-1505.	1.6	16
4	Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 362-373.	10.7	97
5	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	1.9	4
6	Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study. <i>European Urology</i> , 2022, 82, 22-30.	1.9	34
7	Longitudinal screening for depression and anxiety in prostate cancer (PC) and association with disease and treatment factors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5023-5023.	1.6	0
8	Trial in progress: Durvalumab and olaparib for the treatment of prostate cancer in men predicted to have a high neoantigen load.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5099-TPS5099.	1.6	0
9	Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 144-154.	1.9	13
10	Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. <i>JAMA Oncology</i> , 2021, 7, 107.	7.1	90
11	Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations. <i>Current Treatment Options in Oncology</i> , 2021, 22, 13.	3.0	12
12	Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.. <i>Journal of Clinical Oncology</i> , 2021, 39, 435-435.	1.6	1
13	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	2.5	18
14	SGNTUC-019: Phase II basket study of tucatinib (TUC) and trastuzumab (Tras) in previously treated solid tumors with HER2 alterations: Urothelial cancer cohort (trial in progress).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS499-TPS499.	1.6	1
15	A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS187-TPS187.	1.6	2
16	1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.. <i>Journal of Clinical Oncology</i> , 2021, 39, 450-450.	1.6	10
17	EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 394-394.	1.6	19
18	PET-directed local or systemic therapy intensification in prostate cancer patients with post-prostatectomy biochemical recurrence: A trial of the ECOG-ACRIN Cancer Research Group (EA8191).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS267-TPS267.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. <i>Prostate</i> , 2021, 81, 418-426.	2.3	8
20	BiTE-ing into Prostate Cancer with Bispecific T-cell Engagers. <i>Clinical Cancer Research</i> , 2021, 27, 2675-2677.	7.0	6
21	Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015. <i>Urology</i> , 2021, 149, 154-160.	1.0	4
22	Whole-Body [18F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687. <i>Tomography</i> , 2021, 7, 139-152.	1.8	4
23	Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 125-134.	1.9	4
24	Concordance of DNA damage repair (DDR) gene mutations in paired primary and metastatic prostate cancer (PC) samples. <i>Journal of Clinical Oncology</i> , 2021, 39, 5020-5020.	1.6	0
25	Phase III study of local or systemic therapy Intensification Directed by PET in prostate CAncer patients with post-prostaTEctomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5098-TPS5098.	1.6	1
26	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	5.4	39
27	Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 872-882.	10.7	122
28	Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. <i>Oncologist</i> , 2021, 26, 1026-1034.	3.7	8
29	Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6001-6011.	7.0	13
30	Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 496.e1-496.e8.	1.6	1
31	Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA. <i>JAMA Oncology</i> , 2021, 7, 1378.	7.1	40
32	Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. <i>Nature Reviews Urology</i> , 2021, , .	3.8	6
33	Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 69-76.e4.	1.9	11
34	Central Nervous System Metastasis in Patients With Urothelial Carcinoma: Institutional Experience and a Comprehensive Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e266-e276.	1.9	12
35	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	4.1	70
36	â€œMatchingâ€ the â€œMismatchâ€ Repairâ€ Deficient Prostate Cancer with Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 981-983.	7.0	5

#	ARTICLE	IF	CITATIONS
37	Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes. <i>Bladder Cancer</i> , 2020, 6, 71-81.	0.4	16
38	Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0239686.	2.5	6
39	Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. <i>PLoS ONE</i> , 2020, 15, e0233260.	2.5	63
40	Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. <i>Journal of the National Cancer Institute</i> , 2020, 112, 562-573.	6.3	45
41	Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 486-493.	3.9	4
42	Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 436-443.	1.9	1
43	Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity. <i>Clinical Cancer Research</i> , 2020, 26, 2439-2440.	7.0	11
44	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.4	32
45	Complexities of Next-Generation Sequencing in Solid Tumors: Case Studies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1150-1155.	4.9	5
46	Treatment of metastatic recurrence of urothelial carcinoma after previous cisplatin-based chemotherapy: A retrospective comparison of different chemotherapy regimens.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17005-e17005.	1.6	0
47	Perioperative blood transfusion and postoperative outcomes in patients undergoing radical cystectomy for bladder cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17012-e17012.	1.6	0
48	Associations between baseline body composition and cancer-specific mortality following neoadjuvant chemotherapy and radical cystectomy for bladder cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17015-e17015.	1.6	0
49	Skeletal muscle index and adverse events during a bladder cancer treatment episode.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17016-e17016.	1.6	0
50	DAROL: DARolutamide Observational study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5593-TPS5593.	1.6	0
51	Sarcomatoid urothelial carcinoma: Oncologic outcomes from a tertiary center and SEER-Medicare data.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17033-e17033.	1.6	0
52	Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. <i>JCI Insight</i> , 2019, 4, .	5.0	30
53	Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy. <i>Current Treatment Options in Oncology</i> , 2019, 20, 67.	3.0	12
54	What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations. <i>European Urology Focus</i> , 2019, 5, 162-164.	3.1	7

#	ARTICLE	IF	CITATIONS
55	Chemotherapy regimen is associated with venous thromboembolism risk in patients with urothelial tract cancer. <i>BJU International</i> , 2019, 124, 290-296.	2.5	3
56	Precision therapy in advanced urothelial cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 81-93.	0.7	4
57	Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. <i>Prostate</i> , 2019, 79, 701-708.	2.3	18
58	Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5010-5010.	1.6	3
59	Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5027-5027.	1.6	7
60	Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5029-5029.	1.6	2
61	Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 145-145.	1.6	43
62	Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 170-170.	1.6	3
63	Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 171-171.	1.6	14
64	PD14-07 REAL-TIME IMAGING DEMONSTRATING T-CELL MEDIATED DESTRUCTION OF PROSTATIC ACID PHOSPHATASE (PAP)-EXPRESSING CELLS IN PATIENTS (PTS) TREATED WITH SIPULEUCEL-T (SIP-T). <i>Journal of Urology</i> , 2018, 199, .	0.4	2
65	A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. <i>Investigational New Drugs</i> , 2018, 36, 278-287.	2.6	37
66	Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e483-e490.	1.9	12
67	Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e161-e167.	1.9	3
68	DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 106-110.	1.9	12
69	Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 342-353.	3.8	20
70	A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. <i>PLoS ONE</i> , 2018, 13, e0198389.	2.5	86
71	Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. <i>Prostate</i> , 2018, 78, 1077-1083.	2.3	0
72	Hormone levels following surgical and medical castration: defining optimal androgen suppression. <i>Asian Journal of Andrology</i> , 2018, 20, 405.	1.6	3

#	ARTICLE	IF	CITATIONS
73	Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. <i>Cancer Medicine</i> , 2017, 6, 186-194.	2.8	12
74	Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. <i>Clinical Cancer Research</i> , 2017, 23, 2451-2459.	7.0	58
75	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2017, 389, 67-76.	13.7	1,728
76	Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer. <i>Prostate</i> , 2017, 77, 479-488.	2.3	39
77	Avoiding Undertreatment of Aggressive Prostate Cancer by Early Use of Chemotherapy. <i>JAMA Oncology</i> , 2017, 3, 13.	7.1	5
78	AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. <i>Cancers</i> , 2017, 9, 7.	3.7	49
79	A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling. <i>Prostate</i> , 2016, 76, 1303-1311.	2.3	21
80	Making urothelial carcinomas less immune to immunotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 534-537.	1.6	2
81	Targeting intratumoral androgens: statins and beyond. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 388-395.	3.2	7
82	Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. <i>Medical Oncology</i> , 2016, 33, 77.	2.5	11
83	Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. <i>Nature Medicine</i> , 2016, 22, 369-378.	30.7	572
84	Updated efficacy and > 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4515-4515.	1.6	12
85	Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. <i>Oncotarget</i> , 2016, 7, 82504-82510.	1.8	64
86	Persistent androgen receptor addiction in castration-resistant prostate cancer. <i>Journal of Hematology and Oncology</i> , 2015, 8, 128.	17.0	59
87	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	28.9	2,660
88	Cardiovascular Mortality in Testicular Nonseminomatous Germ Cell Tumors: Does Statistical Significance Imply Clinical Significance?. <i>Journal of Clinical Oncology</i> , 2015, 33, 3075-3077.	1.6	0
89	Selective Estrogen Receptor Alpha Agonist GTx-758 Decreases Testosterone with Reduced Side Effects of Androgen Deprivation Therapy in Men with Advanced Prostate Cancer. <i>European Urology</i> , 2015, 67, 334-341.	1.9	15
90	Delayed Antiandrogen Withdrawal Syndrome After Discontinuation of Bicalutamide. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e51-e53.	1.9	1

#	ARTICLE	IF	CITATIONS
91	Relationships Between Times to Testosterone and Prostate-Specific Antigen Rises During the First Off-Treatment Interval of Intermittent Androgen Deprivation are Prognostic for Castration Resistance in Men With Nonmetastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 10-16.	1.9	16
92	Progress in Understanding What Is Being Statin(ed) in Prostate Cancer. <i>JAMA Oncology</i> , 2015, 1, 428.	7.1	4
93	SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1601-1608.	1.6	44
94	Castration-Resistant Prostate Cancer Bone Metastasis Response Measured by ¹⁸ F-Fluoride PET After Treatment with Dasatinib and Correlation with Progression-Free Survival: Results from American College of Radiology Imaging Network 6687. <i>Journal of Nuclear Medicine</i> , 2015, 56, 354-360.	5.0	55
95	Persistent, Unexplained Leukocytosis Is a Paraneoplastic Syndrome Associated With a Poor Prognosis in Patients With Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e253-e258.	1.9	13
96	Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. <i>Cancer</i> , 2015, 121, 2586-2593.	4.1	155
97	A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2014, 120, 2684-2693.	4.1	105
98	The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions. <i>Asian Journal of Andrology</i> , 2014, 16, 331.	1.6	0
99	Long-Term Survival in Bone-Predominant Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e241-e244.	1.9	6
100	Role of Maximal Endoscopic Resection Before Cystectomy for Invasive Urothelial Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 287-291.	1.9	20
101	Nonresponse to Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Cell Carcinoma of the Bladder. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 210-213.	1.9	9
102	A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 883-892.	2.3	59
103	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. <i>New England Journal of Medicine</i> , 2013, 368, 138-148.	27.0	2,412
104	Bone density testing—essential or extraneous?. <i>Nature Reviews Urology</i> , 2013, 10, 11-12.	3.8	0
105	Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. <i>Advances in Urology</i> , 2013, 2013, 1-6.	1.3	34
106	Long-Term Dynamics of Bone Mineral Density During Intermittent Androgen Deprivation for Men With Nonmetastatic, Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1864-1870.	1.6	40
107	Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2012, 188, 103-109.	0.4	43
108	Advanced Clinical States in Prostate Cancer. <i>Urologic Clinics of North America</i> , 2012, 39, 561-571.	1.8	21

#	ARTICLE	IF	CITATIONS
109	A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2012, 30, 121-121.	1.6	12
110	Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer. Urology, 2011, 77, 1166-1171.	1.0	84
111	C11-Acetate and F-18 FDG PET for Men With Prostate Cancer Bone Metastases. Clinical Nuclear Medicine, 2011, 36, 192-198.	1.3	76
112	Duration of First Off-Treatment Interval Is Prognostic for Time to Castration Resistance and Death in Men With Biochemical Relapse of Prostate Cancer Treated on a Prospective Trial of Intermittent Androgen Deprivation. Journal of Clinical Oncology, 2010, 28, 2668-2673.	1.6	61
113	Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2009, 15, 7421-7428.	7.0	203
114	Positron emission tomography imaging as a cancer biomarker. Expert Review of Molecular Diagnostics, 2007, 7, 659-672.	3.1	21
115	Genetic Alterations in Prostate Cancer. Clinical Prostate Cancer, 2005, 3, 220-229.	2.1	1